Novozymes Biopharma, part of Novozymes A/S, has formed a collaboration with Janssen Research & Development, LLC (Janssen). The agreement will enable Janssen to evaluate Novozymes Biopharma's engineered albumin-based VELTIS technology for potential drug candidates. 

Novozymes’ VELTIS technology represents a series of engineered human albumins which, in combination with a drug candidate, offers the potential for tunable control of the therapeutic half-life. The extended half-life of the albumins offers the potential for reducing the dosing frequency of drugs from daily to every two weeks or monthly.

Together with this new collaboration, Novozymes Biopharma announces a new brand name for its half-life extension platform. Now known as VELTIS, the technology enhances the pharmacokinetics of peptide and protein drugs by potentially reducing dosing frequency of therapeutics to once-per-month while contributing additional benefits through decreased dosage levels and reduced toxicity, according to Novozymes Biopharma..

Source:

Novozymes Biopharma